Cargando…

Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies

Complex cellular targets such as G protein-coupled receptors (GPCRs), ion channels, and other multi-transmembrane proteins represent a significant challenge for therapeutic antibody discovery, primarily because of poor stability of the target protein upon extraction from cell membranes. To assess wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Martin J., Jowett, Amanda, Orecchia, Martin, Ertl, Peter, Ouro-Gnao, Larissa, Ticehurst, Julia, Gower, David, Yates, John, Poulton, Katie, Harris, Carol, Mullin, Michael J., Smith, Kathrine J., Lewis, Alan P., Barton, Nick, Washburn, Michael L., de Wildt, Ruud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188403/
https://www.ncbi.nlm.nih.gov/pubmed/32343620
http://dx.doi.org/10.1080/19420862.2020.1755069
_version_ 1783527305424928768
author Scott, Martin J.
Jowett, Amanda
Orecchia, Martin
Ertl, Peter
Ouro-Gnao, Larissa
Ticehurst, Julia
Gower, David
Yates, John
Poulton, Katie
Harris, Carol
Mullin, Michael J.
Smith, Kathrine J.
Lewis, Alan P.
Barton, Nick
Washburn, Michael L.
de Wildt, Ruud
author_facet Scott, Martin J.
Jowett, Amanda
Orecchia, Martin
Ertl, Peter
Ouro-Gnao, Larissa
Ticehurst, Julia
Gower, David
Yates, John
Poulton, Katie
Harris, Carol
Mullin, Michael J.
Smith, Kathrine J.
Lewis, Alan P.
Barton, Nick
Washburn, Michael L.
de Wildt, Ruud
author_sort Scott, Martin J.
collection PubMed
description Complex cellular targets such as G protein-coupled receptors (GPCRs), ion channels, and other multi-transmembrane proteins represent a significant challenge for therapeutic antibody discovery, primarily because of poor stability of the target protein upon extraction from cell membranes. To assess whether a limited set of membrane-bound antigen formats could be exploited to identify functional antibodies directed against such targets, we selected a GPCR of therapeutic relevance (CCR1) and identified target binders using an in vitro yeast-based antibody discovery platform (Adimab(TM)) to expedite hit identification. Initially, we compared two different biotinylated antigen formats overexpressing human CCR1 in a ‘scouting’ approach using a subset of the antibody library. Binders were isolated using streptavidin-coated beads, expressed as yeast supernatants, and screened using a high-throughput binding assay and flow cytometry on appropriate cell lines. The most suitable antigen was then selected to isolate target binders using the full library diversity. This approach identified a combined total of 183 mAbs with diverse heavy chain sequences. A subset of clones exhibited high potencies in primary cell chemotaxis assays, with IC(50) values in the low nM/high pM range. To assess the feasibility of any further affinity enhancement, full-length hCCR1 protein was purified, complementary-determining region diversified libraries were constructed from a high and lower affinity mAb, and improved binders were isolated by fluorescence-activated cell sorting selections. A significant affinity enhancement was observed for the lower affinity parental mAb, but not the high affinity mAb. These data exemplify a methodology to generate potent human mAbs for challenging targets rapidly using whole cells as antigen and define a route to the identification of affinity-matured variants if required.
format Online
Article
Text
id pubmed-7188403
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-71884032020-05-01 Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies Scott, Martin J. Jowett, Amanda Orecchia, Martin Ertl, Peter Ouro-Gnao, Larissa Ticehurst, Julia Gower, David Yates, John Poulton, Katie Harris, Carol Mullin, Michael J. Smith, Kathrine J. Lewis, Alan P. Barton, Nick Washburn, Michael L. de Wildt, Ruud MAbs Report Complex cellular targets such as G protein-coupled receptors (GPCRs), ion channels, and other multi-transmembrane proteins represent a significant challenge for therapeutic antibody discovery, primarily because of poor stability of the target protein upon extraction from cell membranes. To assess whether a limited set of membrane-bound antigen formats could be exploited to identify functional antibodies directed against such targets, we selected a GPCR of therapeutic relevance (CCR1) and identified target binders using an in vitro yeast-based antibody discovery platform (Adimab(TM)) to expedite hit identification. Initially, we compared two different biotinylated antigen formats overexpressing human CCR1 in a ‘scouting’ approach using a subset of the antibody library. Binders were isolated using streptavidin-coated beads, expressed as yeast supernatants, and screened using a high-throughput binding assay and flow cytometry on appropriate cell lines. The most suitable antigen was then selected to isolate target binders using the full library diversity. This approach identified a combined total of 183 mAbs with diverse heavy chain sequences. A subset of clones exhibited high potencies in primary cell chemotaxis assays, with IC(50) values in the low nM/high pM range. To assess the feasibility of any further affinity enhancement, full-length hCCR1 protein was purified, complementary-determining region diversified libraries were constructed from a high and lower affinity mAb, and improved binders were isolated by fluorescence-activated cell sorting selections. A significant affinity enhancement was observed for the lower affinity parental mAb, but not the high affinity mAb. These data exemplify a methodology to generate potent human mAbs for challenging targets rapidly using whole cells as antigen and define a route to the identification of affinity-matured variants if required. Taylor & Francis 2020-04-28 /pmc/articles/PMC7188403/ /pubmed/32343620 http://dx.doi.org/10.1080/19420862.2020.1755069 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Report
Scott, Martin J.
Jowett, Amanda
Orecchia, Martin
Ertl, Peter
Ouro-Gnao, Larissa
Ticehurst, Julia
Gower, David
Yates, John
Poulton, Katie
Harris, Carol
Mullin, Michael J.
Smith, Kathrine J.
Lewis, Alan P.
Barton, Nick
Washburn, Michael L.
de Wildt, Ruud
Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies
title Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies
title_full Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies
title_fullStr Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies
title_full_unstemmed Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies
title_short Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies
title_sort rapid identification of highly potent human anti-gpcr antagonist monoclonal antibodies
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188403/
https://www.ncbi.nlm.nih.gov/pubmed/32343620
http://dx.doi.org/10.1080/19420862.2020.1755069
work_keys_str_mv AT scottmartinj rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT jowettamanda rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT orecchiamartin rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT ertlpeter rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT ourognaolarissa rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT ticehurstjulia rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT gowerdavid rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT yatesjohn rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT poultonkatie rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT harriscarol rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT mullinmichaelj rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT smithkathrinej rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT lewisalanp rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT bartonnick rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT washburnmichaell rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies
AT dewildtruud rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies